Every one of those 1 sits in a single category, medical-devices. Anne Lockwood is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. The 5 average consequence score is below the beat benchmark of 5.6 in the same window.
Figures are computed live from our source-verified story record
— see our methodology for how impact and
sentiment are derived.
What the coverage shows about Zurich
Every one of those 1 sits in a single category, medical-devices. Anne Lockwood is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. The 5 average consequence score is below the beat benchmark of 5.6 in the same window. Each story carries 4 original sources on average, compared with 4.7 for the broader beat in this window. Zurich appears in 1 tracked Healthcare story from February 26, 2026.
Stories tracked
1
Sources per story
4
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 41 Healthcare stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Appears alongside
Other entities that clear the same relevance threshold in stories also covering Zurich. Shared-story counts are live from our verified record — not editorial picks.
Genetic Signatures (ASX:GSS) reported a modest revenue increase for H1 FY26 but warned of unsustainable cash burn and declining gross margins. The company is now pivoting toward aggressive cost-cutting and operational restructuring to stabilize its financial position.